Dr. Coogan brings to Biosion over 25 years of experience in leading small and large molecule toxicology efforts across pharma and biotech.

Before joining Biosion, Dr. Coogan was the Founder and Principal of South Basin Associates (SBA).  Prior to founding SBA, Tim worked for 26 years at Johnson & Johnson (J&J). From 2013, he was Vice President and Head of the Biologics Toxicology group in Janssen Biotherapeutics, the former Centocor organization. In 2017, he became Global Head of Nonclinical Safety with overall responsibility for the nonclinical safety assessment of biologic and small molecule therapeutics in the Janssen R&D portfolio. Additionally, Tim served as a member of the First-in-Human Early Development Committee evaluating potential therapeutics in the Janssen portfolio for safe administration in human.

Dr Coogan holds a Ph.D. in Pharmacology from the University of the Sciences (formerly The Philadelphia College of Pharmacy & Science) and is Board Certified in Toxicology (DABT). He completed postdoctoral training at NYU Medical Center.